IceCure Medical (ICCM) Q3 2024 earnings summary

Executive summary

• Achieved significant milestones in 2024, including 36% sales growth and strong financial improvements driven by global adoption of ProSense cryoablation systems.

• ICE3 trial completed with 96.3% recurrence-free rate; positive data published and presented at major conferences.

• FDA advisory panel voted in favor of ProSense for early-stage, low-risk breast cancer; final FDA decision expected Q1 2025.

• U.S. sales infrastructure and reimbursement code for facility expense already established.

• Multiple positive clinical studies published supporting ProSense efficacy and safety across various tumor types.

Financial highlights

• ProSense probe sales rose 36% to $2.32M for the nine months ended September 30, 2024, versus $1.7M last year.

• Total revenue increased 22% to $2.42M from $1.97M year-over-year.

• Gross profit up 41% to $1.03M; gross margin improved to 43% from 37%.

• Non-GAAP gross profit more than doubled to $934K; non-GAAP gross margin rose to 40% from 27%.

• Net loss narrowed to $10.84M ($0.2022/share) from $11.66M ($0.26/share) year-over-year.

• Cash and equivalents were $10.7M as of September 30, 2024, and $10M as of October 31, 2024.

• Raised $8.1M in net proceeds from share sales in 2024.

Outlook and guidance

• FDA decision on ProSense for early-stage breast cancer expected in Q1 2025.

• U.S. sales team ready to scale; plan to grow from current 2 reps to 6–10 by end of 2025 if FDA clearance is granted.

• Terumo expected to file for Japanese regulatory approval in 2025; approval process estimated at one year post-submission.

• Additional clinical data and publications anticipated throughout 2025.

• Interim results from ICESECRET kidney cancer study expected in December 2024.